| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300683 | 海特生物 | 56.33 | 8.37% | 17.94万 | | 10.12亿 | | 002173 | 创新医疗 | 15.34 | 7.72% | 76.57万 | | 11.37亿 | | 301096 | 百诚医药 | 58.45 | 7.09% | 17.58万 | | 10.01亿 | | 000710 | 贝瑞基因 | 14.64 | 4.95% | 56.75万 | | 8.30亿 | | 301293 | 三博脑科 | 50.08 | 3.58% | 14.57万 | | 7.19 Z | | 300149 | 睿智医药 | 14.24 | 3.56% | 134.38万 | | 18.69亿 | | 000504 | *ST生物 | 10.67 | 3.39% | 5.73万 | | 6098.79万 | | 300244 | 迪安诊断 | 16.10 | 1.58% | 37.94万 | | ...

7月31日，医疗服务行业上涨0.06%，今日主力资金流出10.13亿元，成分股18只上涨，24只下跌。 主力资金净流出居前的分别为药明康德（5.09亿元）、爱尔眼科（2.52亿元）、康龙化成（2.14亿 元）、昭衍新药（1.19亿元）、成都先导（6247.01万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1301096百诚医药58.457.091.29亿元12.93%2002044美 年健康5.111.391.09亿元8.9%3002173创新医疗15.347.729399.58万元8.27%4300149睿智医药 14.243.565741.76万元3.07%5603882金域医学30.850.623766.17万元7.95%6301293三博脑科 50.083.582790.86万元3.88%7300244迪安诊断16.11.582710.14万元4.4%8301080百普赛斯56.311.621235.77 万元5.54%9002219新里程2.22-0.89956.46万元7.94%10300347泰格医药68.110.55913.83万元0.52% 来源：金融界 ...

Group 1 - Goldman Sachs highlights certain healthcare services and treatments, such as high-end dental implants, cataract surgeries, and specific vaccines, which are not covered by national health insurance or affected by centralized drug procurement, indicating strong potential for continued growth in out-of-pocket medical spending among the "silver-haired" population (aged 50 and above) [1] - Goldman Sachs has upgraded ratings for several stocks expected to benefit from the growth in high-end out-of-pocket treatment projects, including Eye Care (300015.SZ) and Zhifei Biological (300122.SZ) to "Buy," while also rating Purui Eye Care (301239.SZ) and Straumann (SAUHY.US) as "Buy," and upgrading Shengtong Medical (600763.SH) to "Neutral" [1] Group 2 - Goldman Sachs focuses on the "silver-haired" demographic, which possesses strong consumption capability with net assets exceeding 3 million RMB, estimating a total addressable market (TAM) that will grow from 221 billion RMB (31 billion USD) in 2024 to 963 billion RMB (135 billion USD) by 2035, with a compound annual growth rate (CAGR) of 14.3% [2] - The report indicates that in 2024, this demographic will account for only 3% of the total population aged 50 and above but will contribute 5% of the healthcare spending for this group, with expectations that this contribution will rise to 13% by 2035 [2] - Goldman Sachs projects the CAGR for healthcare spending among individuals aged 50 and above with net assets over 3 million RMB during 2024-2035 under baseline, optimistic, and pessimistic scenarios to be 14%, 19%, and 9% respectively [2]

7月30日下午，并购新浪潮·东莞智造跃升新引擎——东莞资本市场2025年高质量发展大会举行，来 自"政产学研金"各界的代表济济一堂，共同探寻并购重组何以成为企业裂变成长、制造业高端跃升的重 要路径。同时，大会也围绕并购方法论、实操要点、协同生态等关键议题展开深入探讨，为东莞上市公 司提供决策参考与战略借鉴。 本次活动由东莞市委金融办指导，东莞市上市公司协会、东莞市投资控股集团有限公司（下称"投控集 团"）主办，东莞证券、东莞银行、东莞信托、东莞科创集团、智数公司、华联期货协办，南方报业传 媒集团东莞分社承办。 在当前资本市场不断改革深化、并购重组持续活跃的背景下，并购不仅是企业扩张、迭代、开拓的关键 路径，更是驱动"东莞智造"向全球价值链高端跃升的核心引擎。东莞，这座底蕴深厚的制造业名城，坐 拥境内外上市企业84家、上市后备企业347家、专精特新企业超3000家，正加速迈向国际科创制造强 市。本次活动以"并购"为核心议题，不仅全面回顾了2024年资本市场发展成果，也通过园区推介、战略 签约、主题演讲、圆桌论坛等多个重磅环节，凝聚各方并购智慧，全面助力"东莞智造"向高端化、智能 化、国际化迈进。 "政产学研金" ...

Core Points - The article highlights the recognition of 100 individuals from the non-public economic sector as "Outstanding Builders of Socialism with Chinese Characteristics" to encourage and motivate private economic actors [1][2][3] - Among the honorees, 9 individuals are from the textile industry, showcasing the sector's contribution to the economy [2] - The recognition aims to inspire private economic individuals to uphold their ideals, maintain development focus, and contribute to national strategies [3] Summary by Categories Recognition and Awards - A total of 100 individuals have been awarded the title of "Outstanding Builders of Socialism with Chinese Characteristics" by various government departments [1][2] - The textile industry has 9 representatives among the honorees, indicating its significance in the non-public economic sector [2] Economic Contributions - Since the 18th National Congress, the non-public economy in China has achieved sustained, healthy, and high-quality development, contributing to growth stability, innovation promotion, employment increase, and improved living standards [2] - The article emphasizes the role of private economic individuals in implementing major policies and strategies set by the government [2][3] Future Outlook - The article expresses optimism about the future of the non-public economy, encouraging private economic individuals to learn from the honorees and actively participate in national development [3]

天眼查商业履历信息显示，爱尔眼科医院集团股份有限公司，成立于2003年，位于长沙市，是一家以从 事卫生为主的企业。企业注册资本932539.667万人民币，实缴资本9236.79万人民币。公司法定代表人为 陈邦。 金融界消息 截至2025年7月30日收盘，爱尔眼科（300015）报收于13.16元，下跌0.53%，换手率1.5%， 成交量119.13万手，成交金额15.73亿元。 资金流向方面，今日主力资金净流出4293.02万元，占比成交额2.73%。其中，超大单净流出2178.70万 元、占成交额1.38%，大单净流出2114.32万元、占成交额1.34%，中单净流出流入133.86万元、占成交 额0.09%，小单净流入4159.16万元、占成交额2.64%。 爱尔眼科最新一期业绩显示，截至2025一季报，公司营业总收入60.26亿元、同比增长15.97%，归属净 利润10.50亿元，同比增长16.71%，扣非净利润10.60亿元，同比增长25.78%，流动比率1.615、速动比率 1.481、资产负债率33.30%。 通过天眼查大数据分析，爱尔眼科医院集团股份有限公司共对外投资了380家企业，参与招投标 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector is experiencing a strong performance compared to the overall market, driven by policies aimed at reducing price competition and supporting innovative drugs and medical devices [2][11] - The recent policy changes in centralized procurement are expected to alleviate the low-price competition dilemma in the industry, allowing for a shift towards quality and value-based competition [2][11] - There is a growing support for innovative drugs and medical devices from regulatory and payment policies, which is likely to accelerate the development of high-end domestic medical devices [18] Summary by Sections Market Performance - The overall A-share market increased by 1.70%, with the biotechnology sector rising by 1.90%, outperforming the market [23] - The medical services sector led the gains with a 6.73% increase, while chemical pharmaceuticals saw a decline of 1.23% [23] Centralized Procurement Policy - The 11th batch of centralized procurement emphasizes a "reverse involution" approach, moving away from simple lowest price considerations [17] - The average bidding amount for selected products has decreased significantly, indicating a trend towards smaller-scale submissions [11] - The average price drop for the 10th batch reached a historical high of 72.5% [11] Support for Innovation - The National Medical Products Administration has announced measures to enhance the regulatory framework for high-end medical devices, aiming to accelerate their development [18] - The average annual growth rate of spending on innovative drugs by medical insurance is projected to be 40% from 2020 to 2024 [18] Company Recommendations - **Mindray Medical (300760.SZ)**: Strong growth potential due to its leading position in the medical device sector and international expansion [33] - **WuXi AppTec (603259.SH)**: Positioned to benefit from the rapid growth of the global new drug development outsourcing market [33] - **Aier Eye Hospital (300015.SZ)**: Dominates the domestic eye care service market with a robust expansion strategy [33] - **New Industries (300832.SZ)**: A leader in the field of chemiluminescence immunoassay, with strong growth prospects [33] Valuation Metrics - The current price-to-earnings (P/E) ratio for the pharmaceutical sector is 37.98x, compared to the overall A-share market P/E of 20.19x [28]

爱尔眼科属于医疗服务行业，是一家专注于眼科医疗服务的连锁医疗机构。公司通过"分级连锁"模式构 建覆盖全国的眼科医疗网络，并在全球范围内布局医疗、教学、科研及产业投资。 消息面上，爱尔眼科董事长陈邦近日获颁"优秀中国特色社会主义事业建设者"称号。陈邦带领爱尔眼科 从初创企业发展成为全球性眼科医疗集团，并通过创新模式推动医疗资源下沉，提升基层医疗服务能 力。公司还积极履行社会责任，累计支持公益项目873个，覆盖全国31个省份。 资金方面，7月30日主力资金净流出4293.02万元。 风险提示：股市有风险，投资需谨慎。 截至2025年7月30日收盘，爱尔眼科股价报13.16元，较前一交易日下跌0.53%，成交额达15.73亿元。 来源:金融界 ...

Core Viewpoint - The recognition of Chen Bang, Chairman of Aier Eye Hospital Group, as an "Outstanding Builder of Socialism with Chinese Characteristics" highlights the company's significant contributions to the development of eye care and its innovative approach in the healthcare sector [3]. Group 1: Company Development - Aier Eye Hospital Group has grown from a small startup to a global entity with over 50,000 employees, expanding its services across Asia, America, and Europe [2]. - The company has established a "graded chain" management model for eye hospitals, addressing the uneven distribution of medical resources in China through a four-tier network system [2]. Group 2: Innovation and Technology - Aier Eye Hospital emphasizes technological innovation as a key driver for high-quality development, implementing a strategy of "innovation-driven, technology Aier" [2]. - The company is advancing its "digital ophthalmology" initiative to enhance the quality and accessibility of eye care services [2]. Group 3: Social Responsibility - Aier Eye Hospital is committed to ensuring that everyone, regardless of wealth, has the right to eye health, actively pursuing a balance between social responsibility and corporate development [4]. - The company aims to integrate its development with national strategies and social responsibilities, contributing to the modernization of China [4].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The pharmaceutical sector is experiencing a shift from price competition to quality and value competition due to the new procurement policies aimed at alleviating the low-price competition dilemma [2][11] - There is increasing policy support for innovative drugs and medical devices, which is expected to accelerate the development of high-end domestic medical devices [18] Summary by Sections Market Performance - The overall A-share market rose by 1.70%, with the biotechnology sector outperforming at a 1.90% increase [23] - The medical services sector led the gains with a 6.73% increase, while chemical pharmaceuticals saw a decline of 1.23% [23] Procurement Policy Changes - The 11th batch of centralized procurement emphasizes "anti-involution," allowing medical institutions to choose based on brand and requiring the lowest bidders to justify their pricing [17][15] - This policy aims to shift focus from aggressive price competition to quality and value, benefiting leading companies in the industry [15][17] Support for Innovation - Recent announcements from the National Medical Products Administration and the National Healthcare Security Administration indicate a commitment to support the innovation of high-end medical devices and drugs [18] - The average annual growth rate of healthcare spending on innovative drugs is projected at 40% from 2020 to 2024 [18] Company Earnings Forecasts and Ratings - Major companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform" with projected earnings growth [4] - Mindray Medical is expected to see a rise in net profit from 116.7 billion in 2024 to 161.9 billion by 2027, with a PE ratio decreasing from 24.1 to 17.4 over the same period [4] Recommended Stocks - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic healthcare infrastructure and product upgrades [33] - WuXi AppTec is noted for its comprehensive service capabilities in the new drug development sector, poised to benefit from the global outsourcing market [33] - Aier Eye Hospital is recognized for its rapid expansion in the eye care sector, supported by a strong brand and operational capabilities [33]